MHSPC
Clinical trials for MHSPC explained in plain language.
Never miss a new study
Get alerted when new MHSPC trials appear
Sign up with your email to follow new studies for MHSPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Recruiting nowThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Matched conditions: MHSPC
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Recruiting nowThis study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Matched conditions: MHSPC
Phase 2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC